About 11 results found for searched term "61-90-5" (0.055 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M4553 | Tangeretin | Notch |
| Tangeritin; NSC53909; NSC618905; Ponkanetin | ||
| Tangeretin is a flavonoid from citrus fruit peels, and is also selected as a Notch-1 inhibitor, which plays an important role in anti-inflammatory responses and neuroprotective effects in several disease models. | ||
| M9648 | Empesertib | Serine/Threonine Protease |
| BAY1161909; Mps1-IN-5 | ||
| Empesertib (BAY1161909) is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase (IC50 of < 1 nM), with potential antineoplastic activity. | ||
| M10032 | L-Leucine | mTOR |
| L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. | ||
| M11248 | LY2857785 | CDK |
| LY2857785 is a type I reversible ATP-competitive inhibitor of CDK9, CDK8 and CDK7 with IC50 of 11 nM, 16 nM and 246 nM, respectively. | ||
| M13876 | SB-269970 hydrochloride | 5-HT Receptor |
| SB-269970A | ||
| SB-269970 hydrochloride is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 hydrochloride exhibits >50-fold selectivity against other 5-HT receptors. | ||
| M16686 | 3'-O-Methylorobol | Flavonoids |
| 3'-O-Methylorobol | ||
| M25092 | Recaticimab | PCSK9 |
| SHR-1209 | ||
| Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia. | ||
| M42806 | Celite | Others |
| Celite can be used as an excipient, such as filter media, adsorbent. | ||
| M43181 | BCAT-IN-4 | Others |
| BCAT-IN-4 is a BCAT inhibitor. | ||
| M49913 | Clazosentan | Endothelin Receptor |
| Ro 61-1790; VML 588; AXV-034343 | ||
| Clazosentan is a potent, selective endothelin A receptor (ETA receptor) antagonist and inhibits ET-1-mediated vasoconstriction. It can be used in studies related to cerebral vasospasm, vasospasm-associated cerebral infarction and cerebral ischemia. | ||
| M52981 | [D-Ala2]-Met-Enkephalinamide | Opioid Receptor |
| [D-Ala2]-Met-Enkephalinamide, an opioid peptide, is a potent opioid agonist. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
